Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
PEGINTRON and REBETOL Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
July 9th, 2007
Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission has approved combination therapy with PEGINTRON(TM) (peginterferon alfa-2b, 1.5 mcg/kg once weekly) and REBETOL(R) (ribavirin, 800 - 1,200 mg daily) for the treatment of previously untreated adult patients with chronic hepatitis C who are coinfected with clinically stable HIV. Approximately 40 percent of the estimated 2.5 million people living with HIV in Europe are coinfected with the hepatitis C virus (HCV), according to the World Health Organization (WHO). The European Commission approval of this expanded indication for PEGINTRON and REBETOL results in Marketing Authorization with...
Source: Hepatitis Weekly (2007-07-09)
|
